Stocktoria
Karyopharm Therapeutics Inc. KPTI
Karyopharm Therapeutics Inc. (KPTI) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $146.1M at a -134.2% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KPTI | Karyopharm Therapeutics Inc. | 2/9 | — | — | +0.6% |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | 6/9 | 7.73 | 9.5 | +77.1% |
| MGNX | MACROGENICS INC | 2/9 | -12.89 | — | -0.3% |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | 2/9 | — | — | +7.4% |
| LQDA | Liquidia Corp | 3/9 | -4.36 | — | +1031.2% |
| LFCR | LIFECORE BIOMEDICAL, INC. \DE\ | 3/9 | -1.75 | — | +0.5% |
| XNCR | Xencor Inc | 3/9 | 2.23 | — | +13.7% |
About Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
FAQ
Is KPTI financially healthy?
Karyopharm Therapeutics Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does KPTI pay a dividend?
No, Karyopharm Therapeutics Inc. does not currently pay a dividend.
How profitable is KPTI?
In FY2025, Karyopharm Therapeutics Inc. had a net margin of -134.2%.
What is the analyst price target for KPTI?
The average Wall-Street price target for Karyopharm Therapeutics Inc. is $13.50, about 565.0% above the recent price, from 6 analysts (consensus: buy).
Is KPTI a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Karyopharm Therapeutics Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.